Skip to main content
. 2020 Apr 28;2020(4):CD013594. doi: 10.1002/14651858.CD013594

ACTG084, 1992.

Study characteristics
Methods Single arm trial
Participants 42 (after dAmB induction) participants enrolled; 1 excluded after enrolment as diagnosis not confirmed.
Interventions ITRA 200 mg BD for prevention of relapse (maintenance)
Outcomes Relapse (clinical evaluation)
Death
Follow‐up 109 weeks (range 4–134 weeks)
Age Mean 33 (range 16–50) years
Setting USA
Disease severity Not stated
Notes 2/42 participants relapsed